Compensated Awareness Post View
Disclaimer
05/16/2013 - Big Pharma Could Take Notice of Nuvilex Inc.
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, posits that given its current stage of clinical development it is possible that Nuvilex Inc. (OTCQB: NVLX) may eventually attract the interest of large pharmaceutical firms seeking to gain access to its highly efficacious and proprietary technology platform. Nuvilex Inc. (OTCQB: NVLX) is an international firm with a live-cell encapsulation technology initially directed to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
Any arrangement typically begins with a lengthy due diligence process with no guarantees that anything material arises from such due diligence. Still, it is not uncommon that the process results in some form of partnership or collaboration. These collaborations often contain an agreement to assist in funding future research and development, a royalty arrangement should development lead to regulatory approval, and occasionally lead to a direct investment in the targeted company itself.
While many companies enter Phase III clinical trials without a partner, this prospective event is relevant to companies like Nuvilex Inc. (OTCQB: NVLX) since it is not uncommon for collaborative relationships to be formalized ahead of a Phase III clinical trial.
